Guselkumab Dose 3

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Crohn's DiseaseCrohn DiseaseColitis, Ulcerative

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

1

Remicade

Johnson & Johnson

Approved

282

Entyvio

Takeda

Approved

133

Omvoh

Eli Lilly

Approved

84

Trexall

Jazz Pharmaceuticals

Approved

15

Opzelura

Pfizer

Approved

—6

Mycobutin

Pfizer

Approved

—7

Rocaltrol

Jazz Pharmaceuticals

Approved

—8

Calciferol

Jazz Pharmaceuticals

Approved

—9

Levulan

Sun Pharmaceutical Industries, Inc.

Approved

—10

Lamprene

Novartis

Approved

—Show 41 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting·Johnson & Johnson·Preclinical·NCT03466411·1,409 enrolled

Crohn Disease1 trial

CNTO1959CRD3004: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05197049·350 enrolled

Colitis, Ulcerative1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05528510·418 enrolled

Details

Drug Info

Related News